Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Some claims match label language (e.g., plaque psoriasis indication, subcutaneous administration, IL-12/IL-23 p40 target, weight-based dosing, TB evaluation). However, multiple claims about timing of improvement, general clinician reassessment/switching logic, infection risk phrasing, and biologic comparisons are not supported or are broader than the label excerpts provided.
Category Scores
Accurate Statements
Stelara (ustekinumab) is an injection used to treat moderate-to-severe plaque psoriasis.
Indications 1.1: STELARA indicated for adults and pediatric patients 6 years and older with moderate to severe plaque psoriasis; Dosage forms/strengths 3: subcutaneous injection.
Stelara is administered as an injection under the skin (subcutaneous).
Dosage and Administration 2.1: Administer STELARA subcutaneously at Weeks 0 and 4, then every 12 weeks thereafter.
Stelara blocks interleukins IL-12 and IL-23.
Mechanism of Action 12.1: ustekinumab binds to p40 subunit used by both IL-12 and IL-23 cytokines.
Dosing of Stelara depends on the condition and the patient’s weight.
Dosage and Administration 2.1: weight-based dosing for plaque psoriasis (<=100 kg vs >100 kg); 2.3-2.4-2.5: Crohn’s and UC use weight-based IV induction and weight-based pediatric maintenance.
The Stelara dosing schedule typically starts with a loading period and then continues with maintenance doses every set interval.
Dosage and Administration 2.1: subcutaneous at Weeks 0 and 4, then every 12 weeks thereafter.
Pre-treatment screening and ongoing monitoring for Stelara may include evaluation for tuberculosis.
Warnings/Precautions 5.3: Evaluate for tuberculosis prior to initiating; closely monitor during and after treatment.
Pre-treatment screening and ongoing monitoring for Stelara may include review of infection history.
Warnings/Precautions 5.1: avoid initiating in clinically important active infection until resolved/adequately treated; instruct patients to seek medical advice for infection signs and discontinue for serious/clinically significant infections. (Label excerpts do not explicitly mention 'infection history review' but monitoring for infections and active infection evaluation are addressed.)
Unsupported Statements
Stelara is prescribed for people whose psoriasis is not adequately controlled with other treatments or who need systemic therapy.
Label excerpt 1.1 states patients 'who are candidates for phototherapy or systemic therapy' but does not state 'not adequately controlled with other treatments.'
IL-12 and IL-23 play roles in immune pathways that drive plaque formation and inflammation in psoriasis.
Label excerpt provided supports IL-12/IL-23 targeting (12.1) but does not explicitly describe their roles in plaque formation/inflammation.
Many patients see improvement over the first few weeks after starting Stelara.
No label excerpt provided supports this timing claim.
Psoriasis responses to Stelara can take longer than the first few weeks.
No label excerpt provided supports this timing claim.
Clinicians reassess psoriasis control after an initial period to decide whether to continue, adjust, or switch therapy based on improvement in plaques and symptoms.
No label excerpt provided gives such clinician decision guidance (continue/adjust/switch based on plaque/symptom improvement).
Common concerns with psoriasis biologics include injection-site reactions.
The provided label excerpts do not mention injection-site reactions as 'common concerns' or as a frequency for Stelara.
Common concerns with psoriasis biologics include increased risk of infections.
While infections risk is in the label (5.1), the claim is phrased as a general 'common concerns with psoriasis biologics' comparative statement that is not supported by the provided Stelara label excerpts.
Stelara affects immune signaling and can increase susceptibility to certain infections.
Label excerpt supports increased risk of infections (5.1) but the specific phrasing 'immune signaling' and 'susceptibility to certain infections' is broader than the provided label language; no direct 'susceptibility' phrasing in excerpts.
Some people may use topical therapies alongside systemic treatment when using Stelara.
Label excerpt 7.1 states combination with immunosuppressive agents or phototherapy in plaque psoriasis 'has not been evaluated'; it does not support a statement that patients 'may use topical therapies alongside' Stelara.
Decisions about pairing or sequencing treatments with Stelara should come from the treating dermatologist, especially if other systemic immunosuppressants are involved.
No label excerpt provided specifies clinician role ('treating dermatologist') or sequencing guidance.
Stelara is an option among several biologics for psoriasis, including anti-TNF agents, IL-17 inhibitors, and other IL-23 pathway drugs.
The provided label excerpts do not compare Stelara to other biologics or list specific classes as alternatives.
Contradictions
Important Omissions
Absence of the label’s specific administration schedule and weight-based dosing details for plaque psoriasis (e.g., 45 mg vs 90 mg and intervals) within the generalized claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Safety-related claims are partially aligned (infections risk and TB evaluation) but several other safety-adjacent statements are unsupported or broadly generalized (e.g., 'common concerns' and injection-site reactions). Timing and monitoring/decision guidance claims are not supported by the provided excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Several claims are unsupported by the provided STELARA label excerpts (notably treatment-response timing, clinician reassessment/switching guidance, injection-site reaction frequency, topical combination statements, and biologic class comparisons).
Suggested Improvement
Restrict claims to explicit label support: use the exact plaque psoriasis indication wording ('candidates for phototherapy or systemic therapy'), the weight-based subcutaneous dosing schedule (Weeks 0 and 4, then q12w; 45 mg vs 90 mg by weight), and label-supported infection/TB evaluation language without adding generalized 'common concerns' or response-timing/clinical decision algorithms not present in the excerpts.